Evidence map›Paper›PMID 32637655›Full record

ArticleNPJ precision oncology2020

Somatic copy number profiling from hepatocellular carcinoma circulating tumor cells.

Colin M Court, Shuang Hou, Lian Liu, Paul Winograd, Benjamin J DiPardo, Sean X Liu, Pin-Jung Chen, Yazhen Zhu, Matthew Smalley, Ryan Zhang and 9 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ precision oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05242237 (The Prognostic Value of Circulating Tumor Cells Isolated by a Novel Microfluidic Platform in Liver Cancer Patients), which is not on this map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05242237 unknown statusnot on this mapstarted 2021, after this paper: background citation

The Prognostic Value of Circulating Tumor Cells Isolated by a Novel Microfluidic Platform in Liver Cancer Patients

Typeobservational_patient_registrySponsorThe Second Affiliated Hospital of Chongqing Medical UniversityRan2021 to 2024Enrolled300ConditionsHepatocellular Carcinoma, Circulating Tumor Cell, Whole Genome Sequencing
3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 3 institutions in 1 country.

Colin M CourtDepartment of Surgery, University of California, Los Angeles, Los Angeles, CA USA.ORCID 0000-0002-9357-8957
Shuang HouDepartment of Surgery, University of California, Los Angeles, Los Angeles, CA USA.
Lian LiuPacGenomics, llc, Los Angeles, CA USA.
Paul WinogradDepartment of Surgery, University of California, Los Angeles, Los Angeles, CA USA.
Benjamin J DiPardoDepartment of Surgery, University of California, Los Angeles, Los Angeles, CA USA.
Sean X LiuDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA USA.
Pin-Jung ChenDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA USA.
Yazhen ZhuDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA USA.ORCID 0000-0002-2130-8085
Matthew SmalleyDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA USA.ORCID 0000-0002-0509-6502
Ryan ZhangDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA USA.
Saeed SadeghiDepartment of Medicine, Division of Hematology/Oncology, University of California, Los Angeles, Los Angeles, CA USA.
Richard S FinnDepartment of Medicine, Division of Hematology/Oncology, University of California, Los Angeles, Los Angeles, CA USA.
Fady M KaldasDepartment of Surgery, University of California, Los Angeles, Los Angeles, CA USA.
Ronald W BusuttilDepartment of Surgery, University of California, Los Angeles, Los Angeles, CA USA.
Xianghong J ZhouDepartment of Pathology and Laboratory Medicine, University of California, Los Angeles, Los Angeles, CA USA.
Hsian-Rong TsengDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA USA.ORCID 0000-0003-0942-5905
James S TomlinsonDepartment of Surgery, University of California, Los Angeles, Los Angeles, CA USA.
Thomas G GraeberDepartment of Molecular, Cellular, and Integrative Physiology, University of California, Los Angeles, Los Angeles, CA USA.ORCID 0000-0001-8574-9181
Vatche G AgopianDepartment of Surgery, University of California, Los Angeles, Los Angeles, CA USA.
University of California, Los Angeles · USCalifornia NanoSystems Institute · USMacroGenics (United States) · US

Funding

UCLA SPORE IN PROSTATE CANCERP50CA092131 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI FREEMAN, MICHAEL R · 2002 to 2023
$42.6M
TARGETED COMBINATORIAL TREATMENT OF BRAF MELANOMASP01CA168585 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI RIBAS, ANTONI · 2013 to 2017
$8.4M
The UCLA Center in Early Detection of Liver CancerU01CA230705 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Vatche Agopian, Samuel Wheeler French · 2018 to 2026
$6.6M
HCC EV Digital Scoring Assay for assessing treatment response in HCC patientsR01CA253651 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI AGOPIAN, VATCHE, TSENG, HSIAN-RONG · 2020 to 2024
$3.3M
Extracellular Vesicle-Based Digital Scoring Assay for Detecting Early-stage Hepatocellular CarcinomaR01CA255727 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ZHU, YAZHEN · 2021 to 2025
$3.2M
Integrated analysis of HCC CTCs for Liver Transplant Candidate SelectionR01CA246304 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI AGOPIAN, VATCHE, TSENG, HSIAN-RONG · 2020 to 2024
$2.8M
Mammalian models for integrated metabolic and molecular profiling of malignant gliomaR01CA227089 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI GRAEBER, THOMAS G, NATHANSON, DAVID A. · 2018 to 2022
$2.7M
Targeting Genomic Instability in Lethal Neuroendocrine Prostate CancerR01CA222877 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI GRAEBER, THOMAS G, WITTE, OWEN N. · 2018 to 2022
$2.6M
Thermoresponsive NanoVelcro CTC Purification System for Prostate Cancer ProfilingU01CA198900 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI POSADAS, EDWIN MELENCIO, TSENG, HSIAN-RONG · 2015 to 2019
$2.4M
Novel Computation Methods for the Analysis of Cell-Free DNA Sequence DataR01CA246329 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M., LI, WENYUAN · 2019 to 2022
$2.2M
Click Chemistry-Mediated Microfluidic Sorting for HCC CTCsR21CA235340 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI AGOPIAN, VATCHE, TSENG, HSIAN-RONG · 2019 to 2021
$543k
Biomimetic NanoVilli Chips for Extracellular Vesicles in Hepatocellular CarcinomaR21CA240887 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI AGOPIAN, VATCHE, TSENG, HSIAN-RONG · 2020 to 2021
$419k
NCI NIH HHS P01 CA168585NCI NIH HHS P50 CA092131NCI NIH HHS R01 CA222877NCI NIH HHS R01 CA227089NCI NIH HHS R01 CA246304NCI NIH HHS R01 CA246329NCI NIH HHS R01 CA253651NCI NIH HHS R01 CA255727NCI NIH HHS R21 CA216807NCI NIH HHS R21 CA235340NCI NIH HHS R21 CA240887NCI NIH HHS U01 CA198900NCI NIH HHS U01 CA230705
6 · The paper itself

Abstract

Somatic copy number alterations (SCNAs) are important genetic drivers of many cancers. We investigated the feasibility of obtaining SCNA profiles from circulating tumor cells (CTCs) as a molecular liquid biopsy for hepatocellular carcinoma (HCC). CTCs from ten HCC patients underwent SCNA profiling. The Cancer Genome Atlas (TCGA) SCNA data were used to develop a cancer origin classification model, which was then evaluated for classifying 44 CTCs from multiple cancer types. Sequencing of 18 CTC samples (median: 4 CTCs/sample) from 10 HCC patients using a low-resolution whole-genome sequencing strategy (median: 0.88 million reads/sample) revealed frequent SCNAs in previously reported HCC regions such as 8q amplifications and 17p deletions. SCNA profiling revealed that CTCs share a median of 80% concordance with the primary tumor. CTCs had SCNAs not seen in the primary tumor, some with prognostic implications. Using a SCNA profiling model, the tissue of origin was correctly identified for 32/44 (73%) CTCs from 12/16 (75%) patients with different cancer types.

Indexed as

Molecular medicinePrognostic markers

Identifiers

PMID32637655
PMCPMC7331695
OpenAlexW3038987427

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.